SCHEMBL13697498

SCHEMBL13697498

OC1C(O)[C@@H](CCS)O[C@H]1n1cnc2c1N=CNC[C@H]2O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADA P00813 4/20 0.53
AMPD3 Q01432 2/20 0.44
EHMT1 Q9H9B1 1/20 0.36
DNMT1 P26358 2/20 0.36
AHCY P23526 2/20 0.36
ADORA3 P0DMS8 2/20 0.36
ADORA1 P30542 2/20 0.36
DPP4 P27487 1/20 0.35
MEN1 O00255 1/20 0.35
SLC28A1 O00337 1/20 0.35
MAP3K7 O43318 1/20 0.35
SLC28A2 O43868 1/20 0.35
GAPDH P04406 1/20 0.35
MAPK1 P28482 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
STAT6 P42226 1/20 0.35
PI4KA P42356 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Coformycin SCHEMBL8373037 0.87 ADA (0.68) ADAAMPD3DNMT1ADORA3ADORA1
Coformycin SCHEMBL13697497 0.87 ADA (0.68) ADAAMPD3DNMT1ADORA3ADORA1
Coformycin SCHEMBL7796895 0.87 ADA (0.68) ADAAMPD3DNMT1ADORA3ADORA1
Coformycin SCHEMBL442534 0.87 ADA (0.68) ADAAMPD3DNMT1ADORA3ADORA1
Coformycin SCHEMBL13697294 0.87 ADA (0.68) ADAAMPD3DNMT1ADORA3ADORA1
SCHEMBL13697305 0.83 ADA (0.52) ADAAMPD3DNMT1AHCYADORA3
SCHEMBL13697300 0.83 ADA (0.52) ADAAMPD3DNMT1AHCYADORA3
SCHEMBL15587685 0.83 ADA (0.52) ADAAMPD3DNMT1AHCYADORA3
SCHEMBL14437410 0.83 ADA (0.52) ADAAMPD3DNMT1AHCYADORA3
SCHEMBL15587683 0.83 ADA (0.52) ADAAMPD3DNMT1AHCYADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227532-A1 Analogues of Coformycin and Their Use for Treating Protozoan Parasite Infections ALBERT EINSTEIN COLLEGE OF MEDICINE 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227532-A1 Analogues of Coformycin and Their Use for Treating Protozoan Parasite Infections PDF, PPIF, MT-CO1 ADA 2697/4885AMPD3 229/4885EHMT1 3973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.